Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 0218

Next Previous
Search
Drug Profile

SP 0218

Alternative Names: SP-0218; vYF - Sanofi; Yellow fever vaccine - Sanofi

Latest Information Update: 22 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi Pasteur
  • Developer Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Yellow fever

Most Recent Events

  • 27 Apr 2024 Immunogenicity and adverse events data from phasw IIb trial in Yellow fever presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMID-2024)
  • 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Yellow fever (Prevention) (SC), in 2026 or beyond (Sanofi pipeline, February 2024)
  • 08 Jul 2021 Phase-II clinical trials in Yellow fever (Prevention) in Spain, Finland, Germany (SC) (EudraCT2020-005566-33) (NCT05011123)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top